• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Recent Advances in the Synthesis and Applications of (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol (CAS: 103322-56-1)

The compound (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol (CAS: 103322-56-1) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile role as a chiral building block in the synthesis of bioactive molecules. Recent studies have focused on optimizing its synthetic pathways, exploring its applications in drug development, and investigating its potential in asymmetric catalysis. This research brief consolidates the latest findings related to this compound, providing insights into its current and future applications.

One of the key advancements in the synthesis of (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol involves the use of enantioselective reduction techniques. A 2023 study published in the Journal of Organic Chemistry demonstrated a highly efficient catalytic system employing ruthenium-based catalysts to achieve >99% enantiomeric excess (ee) in the reduction of the corresponding ketone precursor. This method not only improves yield but also reduces the need for costly chiral auxiliaries, making the process more economically viable for large-scale production.

In pharmaceutical applications, researchers have utilized (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol as a key intermediate in the synthesis of novel protease inhibitors. A recent patent application (WO2023056789) describes its incorporation into a new class of antiviral compounds targeting SARS-CoV-2 main protease. The cyclohexyl moiety of this compound appears to enhance binding affinity to hydrophobic pockets in the protease active site, while the Boc-protected amino group allows for further functionalization during drug development.

Structural modifications of (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol have also shown promise in the development of anticancer agents. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibit selective inhibition of protein kinases involved in tumor progression. Particularly, the introduction of various substituents at the hydroxyl position has led to compounds with improved pharmacokinetic properties and reduced off-target effects.

Beyond pharmaceutical applications, recent research has explored the use of (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol in materials science. Its chiral structure makes it valuable for constructing liquid crystalline materials with tunable optical properties. A team at MIT has developed a series of chiral dopants based on this scaffold that significantly enhance the performance of liquid crystal displays while maintaining thermal stability.

Analytical methods for characterizing (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol have also seen improvements. Advanced NMR techniques, including 2D-NMR and DOSY experiments, now allow for more precise determination of its purity and stereochemical configuration. These developments are crucial for quality control in both research and industrial settings where high enantiopurity is required.

Looking forward, the versatility of (S)-2-(Boc-amino)-3-cyclohexylpropan-1-ol suggests continued importance in chemical biology research. Current investigations are focusing on its potential in targeted drug delivery systems and as a scaffold for developing enzyme mimetics. The compound's unique combination of structural features - the protected amino group, chiral center, and hydrophobic cyclohexyl moiety - provides multiple handles for chemical modification while maintaining favorable physicochemical properties.

• 188348-00-7(N-Boc-D-cyclohexylglycinol)
• 106930-51-2(Boc-D-Leucinol)
• 82010-31-9(Boc-Leucinol)
• 106946-74-1(Boc-Isoleucinol)
• 141321-53-1(tert-Butyl ((2R,3R)-1-hydroxy-3-methylpentan-2-yl)carbamate)
• 142121-48-0(N-Boc-DL-Leucinol)
• 107202-39-1((S)-Tert-Butyl (1-cyclohexyl-2-hydroxyethyl)carbamate)
• 129593-17-5(D-Boc-cyclohexylalaninol)
• 137258-12-9(tert-butyl N-(1-hydroxyhexan-2-yl)carbamate)
• 545433-88-3(Carbamic acid, [1-(hydroxymethyl)-2-methylbutyl]-, 1,1-dimethylethyl ester)